DESTINY-Breast04 was a phase 3 trial in which 557 patients with pretreated (endocrine treatment if HR-positive, plus 1–2 prior lines of chemotherapy), advanced HER2-low breast cancer were randomized 2:1 to receive T-DXd or chemotherapy of physician's choice [12]. The gene discussed is ERBB2; the disease is breast carcinoma.